Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor

Abstract

The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CHor CHR; Ris H, C,-C-alkyl, C,-C-alkyl substituted by C-C-cycloalkyl, C-C-hydroxyalkyl, fluorinated C,-C-alkyl, C-C-cycloalkyl, fluorinated C-C-cycloalkyl, C-Calkenyl, fluorinated C-C-alkenyl, formyl, acetyl or propionyl; R, Rand Rare, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF; E is NRor CH, wherein Ris H or C-C-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR, where Ris H, C-C-alkyl, fluorinated C-C-alkyl, C-Calkylcarbonyl or fluorinated C-C-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R, wherein the variable Rhas the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.